Free tool
FAERS Monitor: Elitek
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103946 or its brand name (Elitek, Rasburicase). Reports on generic versions are filed under their own applications.
Reports
2,475
Serious
2,236
90% of reports
Hospitalization
1,323
Death reported
683
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- tumour lysis syndrome364
- febrile neutropenia217
- off label use216
- acute kidney injury148
- pyrexia147
- drug ineffective140
- neutropenia137
- cytokine release syndrome133
- sepsis104
- multiple organ dysfunction syndrome103
- anaemia96
- respiratory failure95
- hypotension90
- pneumonia82
- renal failure81
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 8 |
| 2006 | 5 |
| 2007 | 18 |
| 2008 | 12 |
| 2009 | 11 |
| 2010 | 27 |
| 2011 | 40 |
| 2012 | 54 |
| 2013 | 57 |
| 2014 | 63 |
| 2015 | 76 |
| 2016 | 96 |
| 2017 | 139 |
| 2018 | 243 |
| 2019 | 155 |
| 2020 | 195 |
| 2021 | 251 |
| 2022 | 222 |
| 2023 | 199 |
| 2024 | 229 |
| 2025 | 190 |
| 2026 | 178 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,684 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| tumour lysis syndromeSignal | 364 | 366.7 | 332.7 | 126,969 |
| cytokine release syndromeSignal | 133 | 56.7 | 48.0 | 7,183 |
| multiple organ dysfunction syndromeSignal | 103 | 31.0 | 25.7 | 2,955 |
| febrile neutropeniaSignal | 217 | 27.9 | 24.6 | 5,598 |
| respiratory failureSignal | 95 | 11.1 | 9.1 | 863 |
| neutropeniaSignal | 137 | 8.6 | 7.3 | 914 |
| acute kidney injurySignal | 148 | 8.2 | 7.0 | 938 |
| sepsisSignal | 104 | 7.9 | 6.6 | 626 |
| renal failureSignal | 81 | 5.2 | 4.2 | 271 |
| anaemiaSignal | 96 | 4.3 | 3.5 | 240 |
| hypotensionSignal | 90 | 3.8 | 3.1 | 186 |
| pyrexiaSignal | 147 | 3.6 | 3.1 | 279 |
| pneumoniaSignal | 82 | 2.2 | 1.7 | 50 |
| off label useSignal | 216 | 2.1 | 1.8 | 128 |
| drug ineffective | 140 | 0.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.